Erectile dysfunction (ED) arises from vascular insufficiency, endothelial dysfunction, smooth-muscle pathology, or neurogenic impairment — often clustering with metabolic syndrome, atherosclerosis, and diabetes. Stem-cell investigations focus on whether placental mesenchymal stem cells and exosome preparations can regenerate penile vasculature, restore endothelial nitric-oxide-dependent relaxation, and repair cavernous smooth-muscle tissue. With 35 registered trials and 5 currently recruiting, the biological rationale targets restoration of penile erectile mechanics through vascular and tissue regeneration. Early clinical data suggest potential for improving erectile function, increasing rigidity and tumescence duration, and potentially reducing pharmacological dependence on phosphodiesterase-5 inhibitors when stem-cell therapy complements standard medical management.
Erectile dysfunction trials remain relatively small and heterogeneous in outcome measurement. Five actively recruiting studies suggest ongoing clinical interest and demand. Published data report improvements in erectile function scores (International Index of Erectile Function or similar validated scales) following MSC or exosome infusion, with approximately 40–60% of treated patients showing measurable functional improvement within 3–6 months. Some trials documented improved response to phosphodiesterase-5 inhibitors in previously non-responsive patients. Duplex ultrasound studies showed improved cavernous artery flow in responsive cohorts. However, many studies lack sham-procedure controls; placebo effect is substantial in ED trials. Durability and long-term function beyond 12–24 months remain inadequately documented. Mechanism studies provide plausible biological rationale but lack definitive in-vivo confirmation.
Erectile dysfunction stem-cell treatment costs typically range €3,500–7,000 per cycle, reflecting local penile injection or systemic infusion protocols. Exosome-based formulations, when offered, may cost similarly or slightly higher due to manufacturing. Single-infusion protocols are standard; repeat treatments are proposed at 6–12 month intervals if benefit plateaus. Placental MSC sourcing and preparation costs are modest relative to some other conditions. European programmes (Spain, Germany, Italy) typically charge €4,000–6,000; private boutique andrology clinics may exceed €7,000. Ancillary costs — baseline erectile function assessment, penile Duplex ultrasound — add £500–1,500 but are essential for outcome measurement.
Cell therapy for Erectile Dysfunction is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Erectile Dysfunction programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Erectile Dysfunction overview · Erectile Dysfunction cost →
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية